Financials data is unavailable for this security.
Cash flow in USDView more
In 2023, Inozyme Pharma Inc did not generate a significant amount of cash. Cash Flow from Financing totalled 125.97m or -- of revenues. In addition the company used 70.68m for operations while cash used for investing totalled 53.65m.
Cash flow per share | -1.45 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 1.52 |
---|---|
Tangible book value per share | 1.52 |
More ▼
Balance sheet in USDView more
Current ratio | 9.84 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.4801 |
---|---|
Total debt/total capital | 0.3244 |
More ▼